Drug Discovery Assay Platforms

ICE Bioscience has built a comprehensive set of drug discovery assay platforms that cover the full journey from target validation to preclinical candidate selection. Our platforms integrate biochemical, cellular, biophysical and in vivo technologies to deliver consistent, decision-ready data for biotech and pharmaceutical partners worldwide.

Our Core Platforms

• Target-based assay platforms — kinases, GPCRs, ion channels, epigenetic enzymes, nuclear receptors, transporters and DNA damage repair targets
• Cell-based assay platforms — proliferation and viability assays, reporter gene assays, cell signaling and functional cellular assays
• Biophysical platforms — SPR, ITC, TSA, nanoDSF, MST-TRIC, Spectral Shift and intact mass spectrometry
• In vitro safety platforms — hERG testing, safety pharmacology panels and ion channel selectivity profiling
• In vivo pharmacology platforms — oncology, neuroscience and cardiovascular disease models
• DMPK platforms — in vitro ADME assays and in vivo pharmacokinetic studies

An Integrated Approach

Because these platforms operate under one roof, compounds can move seamlessly from primary screening to selectivity profiling, safety assessment and in vivo efficacy testing. This integration shortens timelines, reduces handover risk and keeps data interpretation consistent across your program.

If you would like to learn more about this service or discuss your project, please contact our team for a tailored proposal and quotation.